Peripheral neuropathy after bone marrow transplantation.
Peripheral neuropathy after bone marrow transplantation can produce motor disability with significant morbidity and mortality, particularly when the neuropathy occurs within the first few months of the transplant. Most of these severe neuropathies have demyelinating features on electrophysiologic tests and histopathology, characteristic of immunologically-mediated neuropathies. The specific immune mechanism is uncertain. It is possible that cyclosporin, FK-506, and interferon-alpha may all trigger immunologically mediated neuropathies in rare patients. Transplants in patients with pre-existing demyelinating neuropathy may result in abrupt exacerbation of the neuropathy. Other causes of severe neuropathies include high-dose cytosine arabinoside and critical illness polyneuropathy. Less severe neuropathies with primarily sensory deficits may result from etoposide conditioning, thalidomide treatment for graft-versus-host disease, and the chemotherapeutic agents cisplatin and paclitaxel when used at high-dose with peripheral stem cell support. When encountering patients with disabling motor neuropathies, transplant physicians must identify (with the aid of nerve conduction tests) those neuropathies that are likely to be immunologically mediated and then empirically add or alter immunosuppressant therapies. Unfortunately, experience has been too limited to suggest specific regimens or the optimal sequence of immunosuppressant therapies.
Openshaw
H
H
Department of Neurology, City of Hope National Medical Center, Duarte, CA 91010-3000, USA.
D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000401:mortality; D016572:Cyclosporine / Q000009:adverse effects; D003561:Cytarabine / Q000009:adverse effects; D003711:Demyelinating Diseases / Q000150:complications; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016898:Interferon-alpha / Q000009:adverse effects; D010523:Peripheral Nervous System Diseases / Q000209:etiology*; D016559:Tacrolimus / Q000009:adverse effects; D013997:Time Factors
D007166:Immunosuppressive Agents; D016898:Interferon-alpha; D003561:Cytarabine; D016572:Cyclosporine; D016559:Tacrolimus